Archon Biosciences: Funding, Investors & Team (Sep 2026)
Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specifiUK antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. Archon Biosciences is based in Seattle and supported by a team of forward-thinking investors led by Madrona Ventures. Our AbC platform was invented with the science and technology recognized by the 2024 Nobel Prize in Chemistry at the Baker Lab in the Institute for Protein Design (IPD).
Archon Biosciences has raised $20.0M across 1 funding round on record, the most recent a Seed of $20.0M announced in Oct 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Archon Biosciences Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Archon Biosciences Funding Rounds
Archon Biosciences Founders and Leadership Team
Contact details for the Archon Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →Archon Biosciences Funding Compared to Other Biotechnology Startups
Archon Biosciences' latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Archon Biosciences in Biotechnology and Washington
Companies Similar to Archon Biosciences
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Archon Biosciences Funding FAQs
What does Archon Biosciences do?
Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specifiUK antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. Archon Biosciences is based in Seattle and supported by a team of forward-thinking investors led by Madrona Ventures. Our AbC platform was invented with the science and technology recognized by the 2024 Nobel Prize in Chemistry at the Baker Lab in the Institute for Protein Design (IPD).
How much funding has Archon Biosciences raised?
Archon Biosciences has raised $20.0M across 1 round on record. The most recent is a Seed of $20.0M announced in Oct 2024.
When did Archon Biosciences last raise funding?
Archon Biosciences' most recent funding round on record is a Seed of $20.0M, announced in Oct 2024.
Who founded Archon Biosciences?
FundedIQ lists James Lazarovits (Founder) at Archon Biosciences.
Where is Archon Biosciences headquartered?
Archon Biosciences is based in Washington, District of Columbia, United States.
How many employees does Archon Biosciences have?
Archon Biosciences is in the 11-50 employee band.
How does Archon Biosciences' funding compare to other Biotechnology startups?
Archon Biosciences' latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Archon Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Archon Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.